Comprehensive Stock Comparison
Compare Cryo-Cell International, Inc. (CCEL) vs Fresenius Medical Care AG & Co. KGaA (FMS) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | CCEL | 2.0% revenue growth vs FMS's 1.5% |
| Value | FMS | Lower P/E (9.9x vs 67.4x) |
| Quality / Margins | FMS | 5.0% net margin vs CCEL's 1.3% |
| Stability / Safety | CCEL | Beta 0.16 vs FMS's 0.40 |
| Dividends | CCEL | 7.3% yield; FMS pays no meaningful dividend |
| Momentum (1Y) | FMS | +0.2% vs CCEL's -55.4% |
| Efficiency (ROA) | FMS | 3.2% ROA vs CCEL's 0.6% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Cryo-Cell International is a cellular processing and cryogenic storage company that preserves umbilical cord blood and tissue stem cells for family use. It generates revenue primarily from cord blood and cord tissue storage services—charging initial processing fees and annual storage fees—with additional income from selling its PrepaCyte CB processing technology to other storage facilities. The company's competitive advantage lies in its established reputation in the family cord blood banking market, proprietary processing technology, and direct-to-consumer marketing relationships with healthcare providers.
Fresenius Medical Care is a global leader in dialysis care and products for patients with chronic kidney failure. It generates revenue through two main segments: dialysis services (about 75% of revenue) from its network of outpatient clinics and hospital contracts, and dialysis products (about 25%) including machines, dialyzers, and related supplies. The company's key advantage is its vertically integrated model—combining clinics, products, and services—which creates patient stickiness and economies of scale in the capital-intensive dialysis industry.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
FMS leads in 3 of 6 categories (Valuation Metrics, Total Returns). CCEL leads in 1 (Profitability & Efficiency). 2 tied.
Financial Metrics (TTM)
FMS is the larger business by revenue, generating $19.6B annually — 618.3x CCEL's $32M. Profitability is closely matched — net margins range from 5.0% (FMS) to 1.3% (CCEL).
| Metric | CCELCryo-Cell Interna… | FMSFresenius Medical… |
|---|---|---|
| RevenueTrailing 12 months | $32M | $19.6B |
| EBITDAEarnings before interest/tax | $6M | $3.3B |
| Net IncomeAfter-tax profit | $399,609 | $978M |
| Free Cash FlowCash after capex | $6M | $1.2B |
| Gross MarginGross profit ÷ Revenue | +77.1% | +25.6% |
| Operating MarginEBIT ÷ Revenue | +13.6% | +9.3% |
| Net MarginNet income ÷ Revenue | +1.3% | +5.0% |
| FCF MarginFCF ÷ Revenue | +19.1% | +6.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | -3.0% | -0.3% |
| EPS Growth (YoY)Latest quarter vs prior year | -30.8% | +8.5% |
Valuation Metrics
At 11.8x trailing earnings, FMS trades at a 82% valuation discount to CCEL's 67.4x P/E. On an enterprise value basis, FMS's 6.3x EV/EBITDA is more attractive than CCEL's 10.0x.
| Metric | CCELCryo-Cell Interna… | FMSFresenius Medical… |
|---|---|---|
| Market CapShares × price | $27M | $13.6B |
| Enterprise ValueMkt cap + debt − cash | $40M | $24.4B |
| Trailing P/EPrice ÷ TTM EPS | 67.40x | 11.84x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 9.89x |
| PEG RatioP/E ÷ EPS growth rate | — | 2.32x |
| EV / EBITDAEnterprise value multiple | 9.97x | 6.33x |
| Price / SalesMarket cap ÷ Revenue | 0.85x | 0.59x |
| Price / BookPrice ÷ Book value/share | — | 0.81x |
| Price / FCFMarket cap ÷ FCF | 7.53x | — |
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), CCEL scores 7/9 vs FMS's 5/9, reflecting strong financial health.
| Metric | CCELCryo-Cell Interna… | FMSFresenius Medical… |
|---|---|---|
| ROE (TTM)Return on equity | — | +6.8% |
| ROA (TTM)Return on assets | +0.6% | +3.2% |
| ROICReturn on invested capital | — | +5.6% |
| ROCEReturn on capital employed | +8.3% | +6.9% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 5 |
| Debt / EquityFinancial leverage | — | 0.76x |
| Net DebtTotal debt minus cash | $12M | $9.2B |
| Cash & Equiv.Liquid assets | $560,960 | $1.6B |
| Total DebtShort + long-term debt | $13M | $10.8B |
| Interest CoverageEBIT ÷ Interest expense | 1.62x | 6.84x |
Total Returns (with DRIP)
A $10,000 investment in FMS five years ago would be worth $7,718 today (with dividends reinvested), compared to $5,120 for CCEL. Over the past 12 months, FMS leads with a +0.2% total return vs CCEL's -55.4%. The 3-year compound annual growth rate (CAGR) favors FMS at 9.1% vs CCEL's 1.7% — a key indicator of consistent wealth creation.
| Metric | CCELCryo-Cell Interna… | FMSFresenius Medical… |
|---|---|---|
| YTD ReturnYear-to-date | -1.7% | -0.2% |
| 1-Year ReturnPast 12 months | -55.4% | +0.2% |
| 3-Year ReturnCumulative with dividends | +5.2% | +29.7% |
| 5-Year ReturnCumulative with dividends | -48.8% | -22.8% |
| 10-Year ReturnCumulative with dividends | +31.2% | -28.5% |
| CAGR (3Y)Annualised 3-year return | +1.7% | +9.1% |
Risk & Volatility
CCEL is the less volatile stock with a 0.16 beta — it tends to amplify market swings less than FMS's 0.40 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. FMS currently trades 77.0% from its 52-week high vs CCEL's 42.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CCELCryo-Cell Interna… | FMSFresenius Medical… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.16x | 0.40x |
| 52-Week HighHighest price in past year | $7.91 | $30.46 |
| 52-Week LowLowest price in past year | $3.10 | $20.95 |
| % of 52W HighCurrent price vs 52-week peak | +42.6% | +77.0% |
| RSI (14)Momentum oscillator 0–100 | 49.7 | 49.0 |
| Avg Volume (50D)Average daily shares traded | 13K | 518K |
Analyst Outlook
CCEL is the only dividend payer here at 7.30% yield — a key consideration for income-focused portfolios.
| Metric | CCELCryo-Cell Interna… | FMSFresenius Medical… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold |
| Price TargetConsensus 12-month target | — | $28.00 |
| # AnalystsCovering analysts | — | 18 |
| Dividend YieldAnnual dividend ÷ price | +7.3% | — |
| Dividend StreakConsecutive years of raises | 0 | 3 |
| Dividend / ShareAnnual DPS | $0.25 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +5.2% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| Cryo-Cell Internati… (CCEL) | 100 | 47.14 | -52.9% |
| Fresenius Medical C… (FMS) | 100 | 56.36 | -43.6% |
Fresenius Medical C… (FMS) returned -23% over 5 years vs Cryo-Cell Internati… (CCEL)'s -49%.
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Cryo-Cell Internati… (CCEL) | $23M | $32M | +38.3% |
| Fresenius Medical C… (FMS) | $17.0B | $19.6B | +15.3% |
Fresenius Medical Care AG & Co. KGaA's revenue grew from $17.0B (2016) to $19.6B (2025) — a 1.6% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Cryo-Cell Internati… (CCEL) | -5.7% | 1.3% | +122.0% |
| Fresenius Medical C… (FMS) | 6.9% | 5.0% | -28.2% |
Fresenius Medical Care AG & Co. KGaA's net margin went from 7% (2016) to 5% (2025).
Chart 4P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Cryo-Cell Internati… (CCEL) | 32.2 | 148.2 | +360.2% |
| Fresenius Medical C… (FMS) | 25.3 | 14.2 | -43.9% |
Cryo-Cell International, Inc. has traded in a 13x–148x P/E range over 6 years; current trailing P/E is ~67x. Fresenius Medical Care AG & Co. KGaA has traded in a 10x–39x P/E range over 9 years; current trailing P/E is ~12x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Cryo-Cell Internati… (CCEL) | -0.16 | 0.05 | +131.3% |
| Fresenius Medical C… (FMS) | 1.87 | 1.68 | -10.2% |
Fresenius Medical Care AG & Co. KGaA's EPS grew from $1.87 (2016) to $1.68 (2025) — a -1% CAGR.
Chart 6Free Cash Flow — 5 Years
Cryo-Cell International, Inc. generated $4M FCF in 2024 (+270% vs 2021). Fresenius Medical Care AG & Co. KGaA generated $0M FCF in 2025 (-100% vs 2021).
CCEL vs FMS: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is CCEL or FMS a better buy right now?
Fresenius Medical Care AG & Co. KGaA (FMS) offers the better valuation at 11.8x trailing P/E (9.9x forward), making it the more compelling value choice. Analysts rate Fresenius Medical Care AG & Co. KGaA (FMS) a "Hold" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CCEL or FMS?
On trailing P/E, Fresenius Medical Care AG & Co. KGaA (FMS) is the cheapest at 11.8x versus Cryo-Cell International, Inc. at 67.4x.
03Which is the better long-term investment — CCEL or FMS?
Over the past 5 years, Fresenius Medical Care AG & Co. KGaA (FMS) delivered a total return of -22.8%, compared to -48.8% for Cryo-Cell International, Inc. (CCEL). A $10,000 investment in FMS five years ago would be worth approximately $8K today (assuming dividends reinvested). Over 10 years, the gap is even starker: CCEL returned +31.2% versus FMS's -28.5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CCEL or FMS?
By beta (market sensitivity over 5 years), Cryo-Cell International, Inc. (CCEL) is the lower-risk stock at 0.16β versus Fresenius Medical Care AG & Co. KGaA's 0.40β — meaning FMS is approximately 144% more volatile than CCEL relative to the S&P 500.
05Which has better profit margins — CCEL or FMS?
Fresenius Medical Care AG & Co. KGaA (FMS) is the more profitable company, earning 5.0% net margin versus 1.3% for Cryo-Cell International, Inc. — meaning it keeps 5.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CCEL leads at 10.9% versus 9.3% for FMS. At the gross margin level — before operating expenses — CCEL leads at 75.2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — CCEL or FMS?
In this comparison, CCEL (7.3% yield) pays a dividend. FMS does not pay a meaningful dividend and should not be held primarily for income.
07Is CCEL or FMS better for a retirement portfolio?
For long-horizon retirement investors, Cryo-Cell International, Inc. (CCEL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.16), 7.3% yield). Both have compounded well over 10 years (CCEL: +31.2%, FMS: -28.5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between CCEL and FMS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: CCEL is a small-cap income-oriented stock; FMS is a mid-cap deep-value stock. CCEL pays a dividend while FMS does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.